Progenity, Inc

Seite 1 von 7
neuester Beitrag: 16.08.22 05:33
eröffnet am: 01.09.21 19:58 von: Tiger Anzahl Beiträge: 153
neuester Beitrag: 16.08.22 05:33 von: renduran Leser gesamt: 30731
davon Heute: 45
bewertet mit 0 Sternen

Seite: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 7   

01.09.21 19:58

12356 Postings, 7597 Tage TigerProgenity, Inc

Rebound? Auffällig , dass seit Tagen der Kurs nach Norden geht! Meinungen?  
Seite: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 7   
127 Postings ausgeblendet.

24.06.22 19:53

75 Postings, 1916 Tage renduran20 % Plus

20 % Plus ist auch ein schönes Statement  

24.06.22 20:11

179 Postings, 510 Tage DjangoNYCPROG

Go go go  

25.06.22 10:19

75 Postings, 1916 Tage renduranBiora

Biora Therapeutics Announces Presentation at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
June 22, 2022
SAN DIEGO, June 22, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced the acceptance of an abstract presenting data on the autonomous triggering and injection efficiency of its systemic therapeutics delivery system by the Parenteral Drug Association (PDA) Universe of Pre-Filled Syringes and Injection Devices Conference. This meeting explores the latest technological advances in the drug delivery devices arena and will take place in Palm Springs, California, October 18-19, 2022.
Details of the presentation are as follows:
 Abstract Title: Presenting Author: Session Type: Session Date:
Development of a Submucosal Injection Device for an Oral Biotherapeutic Delivery System Shaoying Nikki Lee, PhD
Poster Session
October 18 & 19
Abstracts will be published by PDA in advance of the conference. The poster presentation will be made available on the Biora Therapeutics website following the conference.
About Biora Therapeutics
Biora Therapeutics is the biotech company that is reimagining therapeutics. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients? lives. Biora envisions a world where patients have access to needle-free drug delivery and better therapeutic outcomes.
For more information, visit or follow the company on LinkedIn or Twitter.
Safe Harbor Statement or Forward-Looking Statements
This press release contains ?forward-looking statements? within the meaning of the ?safe harbor? provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations of our research and development efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ?may,? ?might,? ?will,? ?objective,? ?intend,? ?should,? ?could,? ?can,? ?would,? ?expect,? ?believe,? ?design,? ?estimate,? ?predict,? ?potential,? ?plan? or the negative of these
terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of precision medicine, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding future revenue generating opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, the ongoing COVID-19 pandemic, and those risks described in ?Risk Factors? and ?Management?s Discussion and Analysis of Financial Condition and Results of Operations? in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
(646) 627-8390
Media Contact

29.06.22 09:05

75 Postings, 1916 Tage renduranBiora

Ist hier noch jemand investiert ?  

29.06.22 09:43

27 Postings, 587 Tage tuerschieberJa ich.

30.06.22 08:09

347 Postings, 1063 Tage Havana888...ich auch...

....haben einiges in der Pipeline und jede Menge Patente, aber riskant...ein wahrer Zock, aber ich mag es  

07.07.22 17:03

75 Postings, 1916 Tage renduranKurs- Gegenreaktion

hoffentlich heute nachhaltig für morgen  

07.07.22 17:18

75 Postings, 1916 Tage renduranNasdaq

Aktuell 18% im Plus!!!!  

21.07.22 17:43

75 Postings, 1916 Tage renduran:-)

10.08.22 16:01

75 Postings, 1916 Tage renduranBin ich der einzige der sich freut

Nasdaq über 30% im Plus :-)  

10.08.22 16:02

75 Postings, 1916 Tage renduran??

10.08.22 19:39

867 Postings, 1638 Tage dopeheadbin auch noch...

dabei: freu freu!!!!  

11.08.22 07:00

27 Postings, 587 Tage tuerschieberGut Ding will weile haben :-)

11.08.22 08:23

12356 Postings, 7597 Tage TigerLäuft doch!

11.08.22 09:20

347 Postings, 1063 Tage Havana888...bin auch noch.. der Hälfte dabei.... Potential ist ja genug vorhanden....Geduld zahlt sich all  

16.08.22 05:33

75 Postings, 1916 Tage renduranZiel 6 Euro - starker Kauf - Analystenmeinung

Seite: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 7   
   Antwort einfügen - nach oben
Werbung zero zero



Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln